Polyethylene Glycol 3350
Active ingredient
Sold as purelax · MiraLAX · gentle lax · COLYTE · RELAXA
- Drug class
- -
- Availability
- Over-the-counter
- Routes
- Oral, Nasogastric
- Markets covered
- 2
- Products on record
- 39
- FDA reports (12 mo)
- 5,568
Overview
Plain-language summary, compiled from the cited regulatory records
Polyethylene Glycol 3350 is an active ingredient used to relieve occasional constipation [1]. It generally produces a bowel movement within one to three days [1].
This ingredient is available under various brand names, including purelax, COMFORTLAX, and Topcare ClearLax [1].
In the past 12 months, there have been 5,568 adverse event reports associated with products containing Polyethylene Glycol 3350 [2]. The most frequently reported issues include the drug being ineffective, product prescribing issues, diarrhea, off-label use, and constipation [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 22 | March 2, 2026 |
| US United States | FDA | 17 | April 23, 2026 |
CACanada· Health Canada
22 products
Uses
PLENVU (polyethylene glycol 3350, sodium ascorbate, sodium sulfate anhydrous, ascorbic acid, sodium chloride and potassium chloride powder for oral solution) is indicated for cleansing of the colon in preparation for colonoscopy in adults.
3 Pediatrics). 2 Geriatrics Geriatrics (≥ 65 years of age): Evidence from clinical studies suggests that use in the geriatric population is associated with no overall differences in safety or effectiveness. 4 Geriatrics).
How to take
USUnited States· FDA
17 products
Uses
Use • relieves occasional constipation (irregularity) • generally produces a bowel movement in 1 to 3 days
How to take
Drug interactions
Known interactions involving Polyethylene Glycol 3350. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 02550938 · revised March 22, 2025
- [2]FDA DailyMed · 006a9eca-400f-47… · revised March 21, 2025 [PDF]
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.